Novo Nordisk and Hims & Hers have reached an agreement ending their dispute over the sale of compounded versions of Wego's anti-obesity drug. Hims & Hers launched an oral compounded version of semaglutide for an introductory price of $49 per month on a five-month plan, while Wego's starter dose costs $149 per month. Novo Nordisk launched oral Wegovy in January, with 50,000 weekly prescriptions and 170,000 users. Hims & Hers stopped selling the compounded pill after pressure from the FDA and HHS, as well as FDA Commissioner Marty Makary's announcement of action against illegal copies. Novo Nordisk sued Hims & Hers for patent infringement on both the compounded pill and semaglutide injection. The company claims that Hims' formulation uses unlicensed liposomal technology, unlike Wego's SNAC technology, which can lead to risks such as overdose. The deal closes the deal for now.[1][2][3][5]